Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZN-c3 Monotherapy in Advanced Solid Tumors
NCT04972422Phase 1Unknown
- Sponsor
- Zentera Therapeutics
- Start
- Jul 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of azenosertib in solid tumor (2 arms), sponsored by Zentera Therapeutics. Primary endpoints: Incidence and severity of adverse events (AEs) and Incidence and severity of dose-limiting toxicities. Status: unknown.
02
Drugs
azenosertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04972422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04972422.